Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables growth accelerates

Q2 FY2026 accounts payables of $66.66M rose 46.1% year over year, ahead of the -34.0% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -42.1% a year.

Context

  • Accounts payables amounted to 0.7% of revenue in FY2025, down 7.7 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +46.1% holds above the trailing-twelve-month pace of -34.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$66.66M+153.5% QoQ
Last fiscal yearDec 2025
$21.32M-90.9% YoY
LTMJun 2026
$30.41M-34.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.1%——
1 year-90.9%——
3-year CAGR-42.1%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
21.32M USD
Year-over-year change
-90.9%

Accounts Payables vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.0% is the 4th highest of 8, against a peer median of -51.7%.
  • Accounts payables amounts to 1.0% of revenue for AMRX, versus a peer median of 1.8%.
AMRX Competitors
Accounts Payables for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹7.14B INR——2.2%
BHCBausch Health Companies Inc.LTM Jun 2026$366.12M USD-275.5%+1.0%3.4%
PRGOPerrigo Company plcLTM Jun 2026$75.6M USD-470.6%—1.8%
VTRSViatris Inc.LTM Jun 2026$33.2M USD+115.8%—0.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$30.41M USD-34.0%-42.1%1.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$17.4M USD-51.7%-15.7%2.6%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$14.97M USD+372.2%+44.4%1.6%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$12.56M USD-121.6%+83.7%1.7%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$5.96M USD+225.9%-23.6%14.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$0 USD——0.0%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$0 USD——0.0%
Peer median (excluding AMRX) —-51.7%+1.0%1.8%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income10.62M(254.79M)(48.72M)(73.88M)72.06M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
Deferred Income Tax00000
Stock-Based Compensation031.85M26.82M27.77M31.95M
Change in Working Capital(133.59M)(59.95M)(47.19M)(4.07M)(204.52M)
Accounts Receivables(16.31M)(79.07M)125.8M(162.16M)(120.57M)
Inventory(49.02M)(102.4M)(126.18M)(130.53M)(87.03M)
Accounts Payables(43.93M)109.57M(94.45M)235.14M21.32M
Other Working Capital(24.34M)11.95M47.64M53.48M(18.23M)
Other Non-Cash Items131.38M107.81M185.26M109.08M216.93M
Operating Cash Flow241.82M65.1M345.58M295.1M339.99M
Capital Expenditures(47.73M)(90.6M)(69.19M)(74.99M)(70.06M)
Acquisitions (Net)(141.54M)(84.71M)011.99M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.21M)(40.8M)(22.39M)(14.65M)(42.2M)
Investing Cash Flow(194.18M)(174.31M)(69.19M)(63M)(112.26M)
Debt Repayment(79.18M)(38.27M)22.65M(185.12M)26.27M
Common Stock Issued853K0001.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(59.8M)(68.35M)(235.23M)(26.67M)(59.76M)
Financing Cash Flow(138.12M)(106.62M)(212.57M)(211.79M)(31.53M)
Effect of Forex Changes102K(5.68M)65K(999K)(1.68M)
Net Change in Cash(90.38M)(221.51M)63.88M19.31M194.52M
Free Cash Flow194.09M(25.5M)276.39M220.11M269.93M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.